Genomma Lab Q3 2026: Net Income Up 18.6% as Sales Edge Up 1.3%

Sales growth led by Latin America

According to the company, consolidated net sales rose from 4,441.4 million pesos in the third quarter of 2025 to 4,497.6 million pesos. Genomma attributes the increase to the ongoing recovery in Mexico, where sell-out is back to positive, and to a 12.2% rise in Latin America. Continued disruption in the US Hispanic retail market partly offset those gains.

CEO Marco Sparvieri said Mexico improved for the third consecutive quarter and that market share held or grew across every business unit despite a soft market. He said the company's late-June innovation is already driving +39% sell-out growth at clients carrying the new product, and that Suerox reached a record 12.6% value share at its leading retailer.

Margins narrow as the company invests more

Profitability figures were lower than a year ago. Gross profit fell 2.6% to 2,762.1 million pesos, a margin of 61.4% against 63.9% in the prior-year quarter. Genomma, which describes the contraction as 244 basis points, links it mainly to the destruction of returned products in the U.S. market and to higher promotional investment, including the fully absorbed impact of Mexico's new tax on non-caloric sweetened beverages.

• Operating income: 863.6 million pesos (19.2% of sales), down 10.8%
• EBITDA: 944.9 million pesos (21.0% of sales), down 10.3%
• SG&A expenses: down 1.1%

The company says the EBITDA margin was in line with its expectations. It describes the 271 basis-point year-over-year decline as a deliberate decision to invest more in promotional activity and commercial spending to accelerate growth. Operating savings, it says, significantly offset operating expenses and inflation.

Net income rises on financing and FX

Net income increased 18.6% to 514.9 million pesos, or 11.4% of sales, compared with 434.1 million pesos and 9.8% a year earlier. Earnings per share rose from 0.43 to 0.51. According to Genomma, the gain was driven by lower financial expenses and a non-recurring favorable foreign exchange result. Sparvieri also said free cash flow improved versus last year.

Investor Day and what comes next

Management will hold a conference call on Thursday, October 22, 2026, at 1:00 p.m. ET (11:00 a.m. Mexico City time), with Sparvieri, CFO Antonio Zamora and investor relations officer Christianne Ibanez. Nine sell-side analysts cover the stock, listed in Mexico under the ticker LAB B.

Sparvieri said the company enters the fourth quarter "with momentum, a stronger innovation pipeline and a solid balance sheet." On December 3 in New York, Genomma plans to present its new operating model, its execution commitments and its artificial intelligence platform in action. The company says it will show measurable results and the ability to replicate winning playbooks across brands, functions and countries.

For investors, the quarter combines modest top-line growth and higher earnings with compressed operating margins. The Investor Day presentation is the next point at which the company has said it will give more detail on its plans.